CRE-BPa activators encompass a range of chemical compounds specifically tailored to enhance the activity of the CRE-BPa protein, a transcription factor involved in cAMP response element-binding within the cellular environment. These activators work by orchestrating a symphony of intracellular signaling modifications that culminate in the increased activity of CRE-BPa, without altering its expression levels. For example, some activators may function by increasing the levels of intracellular cyclic AMP (cAMP), a pivotal second messenger in the signaling pathways that CRE-BPa is involved in. The elevation of cAMP can lead to the activation of protein kinase A (PKA), which then phosphorylates CRE-BPa, thus promoting its transcriptional activity on cAMP response elements within the DNA. Other activators might interact directly with the protein, altering its conformation in a way that enhances its DNA binding affinity or its interaction with co-activators, resulting in amplified gene transcription.
In addition to mechanisms that involve direct interaction with the CRE-BPa or its immediate signaling components, certain activators may exert their effects by modulating signaling pathways that converge on the protein's activity. This could involve the inhibition of phosphodiesterases, which are enzymes responsible for the breakdown of cAMP, thereby sustaining elevated intracellular cAMP levels conducive to CRE-BPa activation. Another route could be the activation of upstream G protein-coupled receptors (GPCRs) that stimulate adenylyl cyclase, the enzyme responsible for synthesizing cAMP from ATP. By targeting these upstream effectors, the activators ensure an environment ripe for CRE-BPa activation. Moreover, some compounds may work by releasing endogenous modulators that favor CRE-BPa activity, thus indirectly supporting the protein's active state. Collectively, these CRE-BPa activators represent a focused array of compounds that specifically enhance the functional activity of CRE-BPa through a variety of finely-tuned molecular interactions and signaling pathway modulations.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly activates adenylate cyclase, leading to an increase in cAMP levels. Elevated cAMP activates protein kinase A (PKA), which then phosphorylates and activates "protein name", enhancing its functional activity within the cell. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a beta-adrenergic agonist, stimulates adenylate cyclase through G protein-coupled receptor signaling, increasing cAMP levels. This activates PKA, which in turn phosphorylates "protein name", resulting in enhanced activity of this protein. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, leading to elevated cAMP levels by preventing its degradation. The consequent activation of PKA can result in the phosphorylation and activation of "protein name", thereby enhancing its function. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram selectively inhibits phosphodiesterase 4 (PDE4), leading to increased cAMP levels. The subsequent PKA activation phosphorylates "protein name", thus enhancing its activity. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP is a cAMP analog that is resistant to degradation by phosphodiesterases. It activates PKA, leading to the phosphorylation and activation of "protein name". | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl cAMP is a membrane-permeable analog of cAMP that activates PKA. This leads to the phosphorylation and subsequent activation of "protein name". | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine engages beta-adrenergic receptors, which activate adenylate cyclase and increase cAMP levels. This cascade results in PKA activation and the phosphorylation of "protein name", thus enhancing its activity. | ||||||
Adenosine | 58-61-7 | sc-291838 sc-291838A sc-291838B sc-291838C sc-291838D sc-291838E sc-291838F | 1 g 5 g 100 g 250 g 1 kg 5 kg 10 kg | $34.00 $48.00 $300.00 $572.00 $1040.00 $2601.00 $4682.00 | 1 | |
Adenosine acts on its receptors to increase intracellular cAMP levels, leading to the activation of PKA. PKA can then phosphorylate and activate "protein name", which enhances its functional activity. | ||||||